This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of two parts: Part 1 is multiple-cohort study that consists of two sequential multiple-ascending dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability.
| Experimental: Participants of age group 12 to <18 years receiving dose A
Participants of age group 12 to <18 years administered with upadacitinib dose A(weight dependent) as described in the protocol
|
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Other Name: ABT-494
|
| Experimental: Participants of age group 12 to <18 years receiving dose B
Participants of age group 12 to <18 years administered with upadacitinib dose B(weight dependent) as described in the protocol
|
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Other Name: ABT-494
|
| Experimental: Participants of age group 6 to <12 years receiving dose A
Participants of age group 6 to <12 years administered with upadacitinib dose A(weight dependent) as described in the protocol
|
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Other Name: ABT-494
|
| Experimental: Participants of age group 6 to <12 years receiving dose B
Participants of age group 6 to <12 years administered with upadacitinib dose B(weight dependent) as described in the protocol
|
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Other Name: ABT-494
|
| Experimental: Participants of age group 2 to <6 years receiving dose A
Participants of age group 2 to <6 years administered with upadacitinib dose A(weight dependent) as described in the protocol
|
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Other Name: ABT-494
|
| Experimental: Participants of age group 2 to <6 years receiving dose B
Participants of age group 2 to <6 years administered with upadacitinib dose B(weight dependent) as described in the protocol
|
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Other Name: ABT-494
|